Mural Oncology Announces $2.035 Cash Per Share in XOMA Royalty Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Source: Newsfilter
- Transaction Details: Mural Oncology has finalized the additional price per share at $0.000 as per the transaction agreement with XOMA Royalty and its wholly-owned subsidiary, with the acquisition expected to close in early December 2025, marking a significant step in the company's strategic expansion.
- Cash Compensation: The acquisition will provide Mural shareholders with a cash consideration of $2.035 per share, and despite the additional price being $0.000, it reflects the acquirer's recognition of Mural's future potential, which may enhance market confidence in Mural.
- Legal Procedures: The acquisition is subject to approval by the Irish High Court, in accordance with Chapter 1 of Part 9 of the Irish Companies Act 2014, demonstrating the company's commitment to strategic restructuring within a compliant legal framework.
- Market Reaction: Although the acquisition price is low, market reactions to Mural may be influenced by the company's integration capabilities post-acquisition and its future growth potential, prompting investors to monitor subsequent developments to assess long-term value.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
